AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment